Design and synthesis of new 1,2-diaryl-4,5,6,7-tetrahydro-1Hbenzo[ d] imidazoles as selective cyclooxygenase (COX-2) inhibitors

Medicinal Chemistry Research

Volumn 21, Issue 8, 2012, Pages 1869-1875

  Zarghi, A ^a   Reihanfard, H ^a   Arfaei, S ^a   Daraei, B ^b   Hedayati, M ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

COX 1; COX 2; Imidazoles

Indexed keywords

1 (4 ACETAMIDOPHENY) 2 [4 (METHYLSULFONYL)PHENYL] 4,5,6,7 TETRAHYDRO 1H BENZO[D]IMIDAZOLE; 1 (4 CHLOROPHENYL) 2 [4 (METHYLSULFONYL)PHENYL] 4,5,6,7 TETRAHYDRO 1H BENZO[D]IMIDAZOLE; 1 (4 FLUOROPHENYL) 2 [4 (METHYLSULFONYL)PHENYL] 4,5,6,7 TETRAHYDRO 1H BENZO[D]IMIDAZOLE; 1 (4 METHOXYPHENYL) 2 [4 (METHYLSULFONYL)PHENYL] 4,5,6,7 TETRAHYDRO 1H BENZO[D]IMIDAZOLE; 1 (4 METHYLPHENYL) 2 [4 (METHYLSULFONYL)PHENYL] 4,5,6,7 TETRAHYDRO 1H BENZO[D]IMIDAZOLE; 1,2 DIARYL 4,5,6,7 TETRAHYDRO 1H BENZO[D]IMIDAZOLE DERIVATIVE; 2 [4 (METHYLSULFONYL)PHENYL] 1 PHENYL 4,5,6,7 TETRAHYDRO 1H BENZO[D]IMIDAZOLE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

EID: 84866102099     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9709-y     Document Type: Article

References (23)

1. Dogne JM, Hanson J, Supuran C, Pratico D (2006) Coxibs and cardiovascular side effects: from light to shadow. Curr Pharm Des 12:971-975
2. Dogné JM, Supuran CT, Pratico D (2005) Cardiovascular effects of the coxibs. J Med Chem 48:2251-2257
3. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265:16737-16740
4. Gelens E, De Kanter FJJ, Schmitz RF, Sliedregt LAJM, Van Steen BJ, Kruse Chris G, Leurs R, Groen MB (2006) Efficient library synthesis of imidazoles using a multicomponent reaction and microwave irradiation. Mol Divers 10:17-22
5. Ghodsi R, Zarghi A, Daraie B, Hedayati M (2010) Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem 18:1029-1033
6. Herschman HR (1996) Prostaglandin synthase 2. Biochem Biophys Acta 1299:125-140
7. Katori M, Majima M (2000) Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 49:367-392
8. Kawamori T, Rao CV, Seibert K, Reddy BS (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:406-412
9. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648
10. Navidpour L, Shafaroodi H, Abdi KH, Amini M, Ghahremani MH, Dehpour AR, Shafiee A (2006) Design, synthesis and biological evaluation of substituted 3-alkylthio-4,5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors. Bioorg Med Chem 14: 2507-2517
11. Nivsarkar M, Banerjee A, Padh H (2008) Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep 60:692-698
12. Penning TD, Tally JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers R, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2, inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-yrazol-1-yl] benzenesulfonamide (SC-b58635, celecoxib). J Med Chem 40:1347-1365
13. Prasit P, Wang Z, Brideau C, Chan CC, Charlson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini JO, Neil GP, Quellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Tagari P, Therien M, Vikers P, Wong E, Xu L, Young RN, Zamboni R, Boyce S, Rupniak N, Forrest M, Visco D, Patrick D (1999) The discovery of rofecoxib, [MK 966, Vioxx, 4-(40-methylsulfonylphenyl)-3-henyl- 2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 9:1773-1778
14. Riendeau D, Percival MD, Brideau C, Dube CS, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson A, Young RN, Chan CC (2002) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558-566
15. Salimi M, Ghahremani MH, Naderi N, Amini M, Salimi E, Amanlou M, Abidi Kh, Salehi R, Shafiee A (2007) Design, synthesis and pharmacological evaluation of 4-[2-alkylthio-5-(4)-4-substituted phenyl)imidazole-4(5)yl]benzene sulfonamides as selective COX-2 inhibitors. Acta Pharm Sinica 28:1254-1260
16. Scholz M, Ulbrich HK, Dannhardt G (2008) Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem 43:1152-1159
17. Smith WL, DeWitt DL (1996) Prostaglandin endoperoxide H synthases-1 and-2. Adv Immunol 62:167-215
18. Solomon DH (2005) Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 52:1968-1978
19. Srinath P, Rao PN, Knaus EE, Suresh MR (2003) Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res 23:3923-3928
20. Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a metaanalysis. J Natl Cancer Inst 100:1439-1447
21. Vane JR, Botting RM (1998) Anti-inflammatory drugs and their mechanism of action. Inflamm Res 47:S78-S87
22. Zarghi A, Najafnia L, Daraie B, Dadrass OG, Hedayati M (2007) Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett 17:5634-5637
23. Zarghi A, Zebardast T, Daraie B, Hedayati M (2009) Design and synthesis of new 1,3-benzthiazinan-4-one derivatives as selective cyclooxygenase (COX-2) Inhibitors. Bioorg Med Chem 17: 5369-5373